# Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial

> **NCT04344951** · PHASE2 · TERMINATED · sponsor: **Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.** · enrollment: 29 (actual)

## Conditions studied

- Pneumonia, Viral
- Covid-19

## Interventions

- **DRUG:** UNIKINON (Chloroquine phosphate) 200mg tablets

## Key facts

- **NCT ID:** NCT04344951
- **Lead sponsor:** Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-06
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** No clinical efficacy against SARS-CoV-2 recorded
- **Last updated:** 2021-09-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04344951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04344951, "Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04344951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*